New drug shows promise for Hard-to-Treat back pain
NCT ID NCT07339566
First seen Jan 21, 2026 · Last updated May 08, 2026 · Updated 14 times
Summary
This study tests a new drug called xeligekimab for people with non-radiographic axial spondyloarthritis, a condition that causes long-term back pain and stiffness. About 40 adults who have not responded well to standard anti-inflammatory drugs will receive injections of xeligekimab over 12 weeks. The main goal is to see if the drug reduces disease activity by at least 20% (ASAS20) at week 12.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NR-AXIAL SPONDYLOARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 430000, China
Contact
Conditions
Explore the condition pages connected to this study.